Floatz logo

Evomela

Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Xinqiao Hospital of ChongqingPhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

141 Active assets in the Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
FILGRASTIM
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →